Nicotine polacrilex and Salivary hypersecretion - a phase IV clinical study of FDA data

Summary:

Salivary hypersecretion is reported as a side effect among people who take Nicotine polacrilex (nicotine polacrilex), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Nicorette, and have High blood pressure.

The phase IV clinical study analyzes which people have Salivary hypersecretion when taking Nicotine polacrilex. It is created by eHealthMe based on reports of 6,411 people who have side effects when taking Nicotine polacrilex from the FDA, and is updated regularly.

What is Nicotine polacrilex?

Nicotine polacrilex has active ingredients of nicotine polacrilex. It is often used in quit smoking. eHealthMe is studying from 6,437 Nicotine polacrilex users. Check the latest studies of Nicotine polacrilex.

What is Salivary hypersecretion?

Salivary hypersecretion (excess saliva secretion) is found to be associated with 779 drugs and 1,338 conditions by eHealthMe. Check the latest studies of Salivary hypersecretion.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.



On Sep, 02, 2026

6,411 people reported to have side effects when taking Nicotine polacrilex.
Among them, 30 people (0.47%) have Salivary hypersecretion.

Could Nicotine polacrilex cause Salivary hypersecretion?

Among these 30 people:

How long have people been on Nicotine polacrilex when they have Salivary hypersecretion? *

  • < 1 month: 100 %
  • 1 - 6 months: 0.0 %
  • 6 - 12 months: 0.0 %
  • 1 - 2 years: 0.0 %
  • 2 - 5 years: 0.0 %
  • 5 - 10 years: 0.0 %
  • 10+ years: 0.0 %

What is the gender of people who have Salivary hypersecretion when taking Nicotine polacrilex? *

  • female: 63.33 %
  • male: 36.67 %

What is the age of people who have Salivary hypersecretion when taking Nicotine polacrilex? *

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 9.52 %
  • 30-39: 9.52 %
  • 40-49: 23.81 %
  • 50-59: 14.29 %
  • 60+: 42.86 %

What are other drugs people take besides Nicotine polacrilex? *

  1. Nicorette: 3 people, 10.00%
  2. Xanax: 1 person, 3.33%
  3. Janumet: 1 person, 3.33%
  4. Biotin: 1 person, 3.33%
  5. Celexa: 1 person, 3.33%
  6. Coreg: 1 person, 3.33%
  7. Coumadin: 1 person, 3.33%
  8. Fish Oil: 1 person, 3.33%
  9. Incruse Ellipta: 1 person, 3.33%
  10. Magnesium: 1 person, 3.33%

What are other side effects people have besides Salivary hypersecretion? *

  1. Nausea (feeling of having an urge to vomit): 5 people, 16.67%
  2. Drug Ineffective: 4 people, 13.33%
  3. Hiccups (an involuntary spasm of the diaphragm and respiratory organs, with a sudden closure of the glottis and a sound like a cough): 3 people, 10.00%
  4. Oral Discomfort (pain or irritation in mouth): 3 people, 10.00%
  5. Nausea And Vomiting: 2 people, 6.67%
  6. Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 2 people, 6.67%
  7. Throat Irritation: 2 people, 6.67%
  8. Drug Administration Error: 2 people, 6.67%
  9. Indigestion: 2 people, 6.67%
  10. Lacrimation Increased: 2 people, 6.67%

What are the existing conditions these people have? *

  1. High Blood Pressure: 5 people, 16.67%
  2. High Blood Cholesterol: 3 people, 10.00%
  3. Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 2 people, 6.67%
  4. Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 2 people, 6.67%
  5. Chronic Obstructive Pulmonary Disease (a progressive disease that makes it hard to breathe): 2 people, 6.67%
  6. Depression: 2 people, 6.67%
  7. Fungal Infection: 1 person, 3.33%
  8. Asthma: 1 person, 3.33%
  9. Birth Control: 1 person, 3.33%
  10. Bronchitis (inflammation of the mucous membrane in the bronchial tubes): 1 person, 3.33%

* Approximation only. Some reports may have incomplete information.

Do you take Nicotine polacrilex and have Salivary hypersecretion?

- Check whether Salivary hypersecretion is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, long term effects of, and alternative drugs to Nicotine polacrilex:

Salivary hypersecretion treatments and more:

How severe was Salivary hypersecretion and when was it recovered:

Expand to all the drugs that have ingredients of nicotine polacrilex:

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Nicotine polacrilex:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Salivary hypersecretion:

Browse all the conditions that are associated with Salivary hypersecretion:


How the study uses the data?

The study uses data from the FDA. It is based on nicotine polacrilex (the active ingredients of Nicotine polacrilex) and Nicotine polacrilex (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: